infect
human
eastern
equin
enceph
viru
eeev
first
experiment
enceph
marmoset
eeev
alphaviru
sever
human
arthropodborn
diseas
north
america
na
genet
antigen
distinct
strain
south
america
sa
strain
south
american
strain
associ
sever
human
diseas
mortal
confirm
appar
phenotyp
differ
marmoset
infect
use
intranas
rout
monitor
weight
loss
fever
anorexia
depress
neurolog
sign
na
eeevinfect
anim
die
euthan
within
day
due
anorexia
neurolog
sign
sa
eeevinfect
anim
remain
healthi
throughout
cours
experi
even
though
develop
viremia
titer
pfuml
day
infect
interestingli
na
eeevinfect
anim
show
detect
viremia
howev
viru
detect
brain
liver
muscl
na
eeevinfect
anim
time
death
euthanasia
addit
na
eeevinfect
anim
develop
meningoenceph
cerebr
cortex
perivascular
hemorrhag
consist
brain
lesion
describ
human
infect
eeev
experi
confirm
previou
studi
sa
strain
induc
higher
level
viremia
compar
na
eeev
strain
na
strain
show
undetect
transient
level
viremia
induc
enceph
subsequ
death
summari
studi
show
marmoset
use
small
nonhuman
primat
nhp
model
human
eeev
west
nile
viru
wnv
flaviviru
anoth
common
form
arthropodborn
enceph
occur
worldwid
respons
sporad
enceph
part
africa
asia
europ
viru
detect
new
york
citi
spread
rapidli
unit
state
caribbean
central
america
canada
case
neuroinvas
wnv
diseas
unit
state
alon
enzoot
cycl
occur
mosquito
bird
wherea
viru
transmit
via
mosquito
equin
human
twenti
percent
infect
individu
develop
febril
syndrom
howev
less
infect
individu
progress
develop
mening
enceph
paralysi
experiment
infect
common
marmoset
virul
european
wnv
strain
result
product
infect
compar
rhesu
monkey
higher
rate
viral
replic
wider
tissu
distribut
viru
neither
speci
show
behavior
chang
impair
kidney
function
even
though
marmoset
detect
wnv
rna
kidney
tissu
speci
develop
natur
killer
respons
follow
igm
igg
antibodi
respons
common
marmoset
least
suscept
infect
wnv
suscept
macaqu
due
compar
immun
respons
seen
human
could
serv
model
wnv
diseas
dengu
viru
denv
arthropodborn
flaviviru
major
caus
worldwid
morbid
mortal
four
serotyp
denv
denv
transmit
tropic
countri
serotyp
caus
syndrom
selflimit
sever
denv
caus
flulik
diseas
often
refer
breakbon
fever
dengu
hemorrhag
feverdengu
shock
syndrom
dhfdss
character
sudden
vascular
permeabl
hypothes
dhfdss
result
enhanc
crossreact
neutral
antibodi
produc
syndrom
sequenti
dengu
infect
differ
strain
common
marmoset
develop
high
level
viremia
inocul
clinic
isol
four
serotyp
denv
gener
x
genom
copiesml
inocul
rna
detect
lymphoid
organ
includ
lymph
node
spleen
thymu
well
nonlymphoid
organ
lung
liver
kidney
pancrea
urinari
bladder
marmoset
inocul
reinfect
appear
primari
inocul
induc
protect
immun
recent
shown
primari
infect
inocul
heterolog
viru
produc
viremia
viru
well
high
level
neutral
antibodi
titer
challeng
infect
serotyp
inocul
also
serotyp
inocul
primari
infect
serotyp
elicit
lifelong
immun
serotyp
immun
serotyp
short
live
suggest
denv
infect
subtyp
prevent
reinfect
differ
serotyp
crossreact
antibodi
develop
may
complic
immun
respons
seen
human
denv
infect
data
suggest
marmoset
may
prove
valuabl
tool
assess
dengu
vaccin
candid
sever
respiratori
infect
coronavirus
cov
emerg
last
decad
first
sever
respiratori
ill
emerg
sever
acut
respiratori
syndrom
sar
diseas
primarili
present
pneumon
later
progress
renal
gastrointestin
hepat
diseas
common
marmoset
inocul
intratrach
cell
supernat
contain
sarsassoci
pathogen
sarscov
evalu
time
day
infect
anim
develop
multifoc
mononuclear
cell
interstiti
pneumon
multinucl
syncyti
cell
develop
bronchiol
day
infect
viral
rna
detect
pulmonari
extract
sometim
detect
tracheobronchi
lymph
node
myocardium
human
diseas
correl
express
primari
function
receptor
sarscovassoci
patholog
detect
viral
rna
studi
suggest
express
level
similar
human
howev
sarscov
infect
marmoset
present
mani
sever
clinic
sign
respiratori
diseas
observ
human
middl
east
respiratori
syndrom
mer
emerg
etiolog
agent
mer
middl
east
respiratori
syndrom
associ
coronaviru
merscov
estim
decemb
case
mer
countri
outbreak
origin
saudi
arabia
recent
seriou
outbreak
south
korea
updat
marmoset
becam
interest
model
merscov
dipeptidyl
peptidas
also
known
shown
function
receptor
merscov
comparison
marmoset
show
ident
human
marmoset
inocul
via
combin
intratrach
intranas
andor
ocular
rout
marmoset
develop
lethal
pneumonia
extens
lesion
evid
lung
viral
titer
detect
day
postinfect
merscov
rna
detect
blood
suggest
system
dissemin
viral
rna
detect
nearli
tissu
infect
anim
anoth
studi
investig
compar
two
isol
merscov
inocul
via
intratrach
rout
exposur
report
show
marmoset
develop
mildtomoder
nonleth
respiratori
diseas
chan
et
al
abl
improv
outcom
diseas
treatment
lopinavirritonavir
marmoset
intratrach
deliv
merscov
data
support
marmoset
valuabl
nhp
model
merscov
marmoset
recent
evalu
model
variou
hemorrhag
fever
first
hemorrhag
fever
examin
lassa
fever
member
arenavirida
famili
lassa
viru
lasv
caus
agent
lassa
fever
approxim
case
occur
year
western
africa
fatal
rate
mani
hospit
lassa
transmit
rodent
reservoir
mastomi
natalensi
via
rodent
excreta
close
contact
infect
individu
diseas
progress
includ
nausea
vomit
diarrhea
abdomin
pain
hemorrhag
occur
case
common
marmoset
subcutan
inocul
lasv
strain
josiah
inocul
produc
system
diseas
clinic
featur
mimick
fatal
human
lassa
infect
includ
fever
weight
loss
high
level
viremia
viral
rna
found
tissu
elev
liver
enzym
sever
morbid
day
postinfect
importantli
also
multifoc
hepat
necrosi
mild
inflamm
hepatocyt
prolifer
lymphoid
deplet
nephriti
immunophenotyp
alter
spleen
includ
reduct
overal
number
cell
disturb
lymphoid
follicular
architectur
data
show
anim
model
infect
lasv
infect
impair
adapt
immun
note
lasv
infect
human
marmoset
model
subsequ
util
evalu
efficaci
reassort
vaccin
lasv
vaccin
candid
encod
np
gpc
lasv
z
protein
l
protein
mopeia
viru
mopv
mopv
old
world
group
arenavirus
relat
lasv
howev
viru
nonpathogen
experiment
anim
virul
arenavirus
encod
larg
genom
segment
encod
z
l
protein
thu
vaccin
antigen
lasv
virul
mopv
determin
singl
inject
reassort
vaccin
induc
low
transient
viremia
low
moder
level
replic
marmoset
tissu
result
expect
liveattenu
vaccin
vaccin
result
immun
respons
induct
steril
cellmedi
immun
data
support
notion
promis
vaccin
candid
marmoset
could
use
vaccin
treatment
develop
ebola
marburg
virus
marv
member
filovirida
induc
seriou
hemorrhag
diseas
filovirus
commonli
associ
caus
human
diseas
marv
ebola
viru
formerli
known
ebola
zair
ebov
case
fatal
rate
cfr
report
variou
outbreak
rang
averag
mortal
ebov
diseas
estim
marv
diseas
know
outbreak
recent
outbreak
ebov
west
africa
cfr
lowest
ebov
outbreak
gener
held
west
african
outbreak
result
lower
mortal
due
better
support
care
allow
time
immun
system
clear
viru
marmoset
shown
model
filovirusinduc
diseas
marmoset
inocul
intramuscularli
ebov
marv
infect
result
system
fatal
diseas
clinic
featur
resembl
human
infect
anim
experienc
weight
loss
fever
high
viru
titer
tissu
thrombocytopenia
neutrophilia
high
liver
transaminas
phosphatas
dissemin
intravascular
coagul
differ
histopatholog
marv
ebov
ebola
infect
show
widespread
intravascular
coagul
multipl
organ
includ
spleen
adren
gland
kidney
lung
extens
lymphocyt
necrosi
medullari
parafollicular
region
howev
follicl
show
evid
necrosi
extens
fibrin
deposit
marvinocul
anim
moder
fibrin
deposit
spleen
wherea
intravascular
coagul
observ
interestingli
hepat
lesion
less
sever
anim
receiv
higher
dose
viru
suggest
diseas
cours
develop
rapidli
allow
develop
hepat
patholog
also
marmoset
develop
petechi
rash
suggest
rapid
progress
diseas
prevent
symptom
occur
author
suggest
marmoset
similar
diseas
cours
human
diseas
nhp
model
may
superior
other
understand
pathogenesi
filoviru
diseas
develop
vaccin
airborn
filoviru
prioriti
particularli
militari
filovirus
select
agent
therefor
consid
possibl
biowarfar
agent
filovirus
may
aerosol
investig
develop
marmoset
model
marv
deliv
via
respiratori
rout
smither
et
al
show
low
dose
viru
tcid
suffici
caus
lethal
infect
anim
becam
febril
day
succumb
diseas
day
post
challeng
typic
clinic
observ
includ
hemorrhag
anim
transient
rash
small
number
anim
author
suggest
rash
may
due
slightli
longer
durat
diseas
slight
genet
differ
marmoset
differ
background
viru
isol
lung
day
post
challeng
liver
spleen
blood
day
post
challeng
patholog
kidney
liver
day
anim
highest
viral
titer
develop
sever
clinic
symptom
marmoset
expos
low
dose
ebovkikwit
tcid
via
respiratori
rout
develop
lethal
infect
anim
develop
fever
day
postinfect
succumb
infect
day
postinfect
similar
result
marv
marmoset
model
observ
wherebi
ebov
isol
lung
day
post
challeng
liver
spleen
blood
day
post
challeng
anim
die
infect
high
viral
titer
organ
increas
liver
function
enzym
increas
blood
clot
time
decreas
level
platelet
multifoc
moderatetosever
hepat
edema
marmoset
prove
excel
model
human
diseas
anoth
viral
famili
marmoset
hous
indoor
care
biosafeti
level
condit
primarili
protect
anim
acquir
human
infect
util
wide
varieti
koch
postul
experi
prescreen
clade
enterovirus
show
signific
seroconvers
patterson
shigeo
person
commun
yu
et
al
abl
use
marmoset
test
hypothesi
novel
adenoviru
tmadv
isol
titi
monkey
callicebu
cupreu
caus
fulmin
pneumonia
outbreak
coloni
titi
monkey
nation
primat
center
outbreak
becam
signific
human
research
facil
household
famili
show
possibl
crossspeci
transmiss
viru
four
marmoset
inocul
cell
cultureadapt
tmadv
three
marmoset
show
acut
mild
respiratori
ill
character
lowgrad
fever
reduc
activ
anorexia
sneez
monkey
symptom
develop
neutral
antibodi
work
support
notion
marmoset
could
use
assess
zoonot
potenti
adenovirus
aris
human
nhp
similarli
marmoset
shown
model
investig
orthopoxvirus
opv
kramski
et
al
evalu
infect
pathogen
calpox
viru
marmoset
minim
infecti
dose
lower
variola
viru
monkeypox
viru
compar
macaqu
model
later
mucker
et
al
also
show
marmoset
suscept
lower
titer
monkeypox
viru
deliv
via
intraven
rout
incub
period
characterist
human
smallpox
diseas
compar
macaqu
model
overal
deem
suitabl
primat
model
overcom
limit
opv
model
especi
requir
high
viral
dose
appli
unnatur
rout
marmoset
use
model
respiratori
bacillu
anthraci
infect
marmoset
challeng
via
respiratori
rout
smallparticl
aerosol
contain
b
anthraci
ame
strain
ld
colonyform
unit
cfu
compar
cfu
rhesu
macaqu
cfu
cynomolgu
macaqu
time
euthanasia
h
statist
correl
dosag
onset
clinic
sign
dyspnea
disorient
reduc
respons
extern
stimuli
appear
quickli
marmoset
challeng
burkholderia
mallei
via
intranas
rout
challeng
dose
cfu
result
acut
lethal
infect
within
day
postinfect
marmoset
challeng
anim
challeng
lower
infecti
dose
bacteria
develop
mild
sign
ill
cultur
neg
anim
challeng
higher
infecti
dose
develop
sever
clinic
sign
diseas
includ
lethargi
lack
appetit
conjunct
mucopurul
hemorrhag
nasal
discharg
lesion
resembl
seen
human
case
glander
present
tissu
marmoset
also
challeng
escherichia
coli
author
show
e
coli
caus
diarrhea
hemorrhag
typhlocol
seen
captiv
marmoset
marmoset
inocul
three
strain
mycobacterium
tuberculosi
develop
fulmin
diseas
specul
marmoset
could
provid
attract
model
human
diseas
tuberculosi
studi
conduct
mani
nhp
speci
attempt
find
anim
model
iii
research
applic
human
hepat
infect
long
develop
diagnost
assay
hav
hbv
hcv
one
studi
suggest
presenc
new
viru
human
serum
inject
tamarin
saguinu
speci
infect
induc
hepat
base
increas
serum
level
liver
enzym
serum
deriv
patient
initi
gb
gb
agent
character
serial
passag
tamarin
isol
modern
techniqu
provid
molecular
clone
two
virus
tamarin
viral
agent
term
gb
viru
gbva
gb
viru
b
gbvb
show
similar
flavivirida
subsequ
studi
clone
relat
viru
human
serum
design
gbvc
gbva
gbvc
hepat
virus
caus
known
diseas
discuss
origin
studi
assum
gb
agent
origin
serum
surgeon
howev
retrospect
gbvb
clearli
repres
tamarin
viru
gbvb
recov
human
gbvb
narrow
host
rang
tamarin
close
relat
new
world
monkey
fact
recov
second
time
tamarin
may
due
rapid
resolut
acut
infect
tamarin
limit
number
wildcaught
tamarin
examin
immedi
introduct
captiv
sequenc
analysi
gbvb
genom
reveal
singl
orf
amino
acid
amino
acid
similar
hcv
like
hcv
gbvb
genom
encod
singl
polyprotein
protein
possess
ire
intern
ribosom
entri
site
uniqu
ntr
nontransl
region
develop
anim
model
gbvb
major
advantag
gbvb
surrog
hcv
small
size
anim
model
although
tamarin
saguinu
sp
appear
natur
host
viru
adapt
close
relat
marmoset
callithrix
jacchu
see
addit
advantag
increas
level
viremia
often
reach
ge
ml
higher
observ
hcvinfect
human
basi
higher
viremia
known
may
involv
increas
abil
avoid
innat
immun
respons
one
disadvantag
gbvb
model
low
frequenc
persist
infect
infect
normal
resolv
within
month
least
four
tamarin
one
marmoset
lanford
unpublish
data
progress
chronic
infect
insight
differ
gbvb
hcv
develop
persist
infect
may
provid
critic
insight
vaccin
strategi
although
natur
host
gbvb
appear
tamarin
sever
new
world
primat
suscept
infect
marmoset
exhibit
two
distinct
viral
profil
infect
gbvb
suscept
rapid
escal
viremia
partial
resist
clear
delay
maximum
viremia
differ
phenotyp
like
due
genet
polymorph
marmoset
popul
affect
critic
viralehost
interact
serial
passag
wildtyp
gbvb
reach
maximum
viremia
resist
anim
result
adapt
uniform
suscept
profil
subsequ
infect
adapt
viru
contain
nucleotid
chang
amino
acid
chang
howev
note
even
adapt
viru
replic
level
lower
marmoset
compar
tamarin
unlik
hcv
gbvb
readili
cultur
primari
hepatocyt
marmoset
tamarin
decad
research
conduct
hcv
singl
strain
isol
could
replic
uniqu
liver
cancer
cell
line
although
vitro
model
hcv
becom
common
tool
hcv
abil
infect
primari
hepatocyt
use
patientderiv
serum
remain
challeng
gbvb
move
anim
cultur
back
anim
without
requir
adapt
mutat
primari
hepatocyt
cultur
system
gbvb
intact
innat
immun
respons
provid
authent
environ
evalu
abil
viral
protein
subvert
innat
respons
infecti
cdna
clone
gbvb
produc
induc
hepat
intrahepat
inocul
tamarin
marmoset
vitro
transcrib
rna
chimer
virus
gbvb
hcv
develop
mix
success
replac
portion
gbvb
ire
domain
iii
hcv
ire
induc
infect
tamarin
prolong
period
viremia
viru
emerg
two
compensatori
mutat
opposit
end
genom
ntr
region
allow
chimer
rna
replic
effici
unlik
wt
gbvb
chimer
viru
could
adapt
effici
infect
marmoset
highlight
anoth
differ
tamarin
marmoset
model
chimer
virus
also
produc
hcv
replac
gbvb
hcv
hypervari
region
delet
studi
ntr
map
essenti
natur
structur
surprisingli
delet
poli
u
stretch
result
one
document
chronic
infect
proteas
hcv
gbvb
interchang
regard
process
polyprotein
high
level
function
homolog
led
expect
antivir
compound
develop
hcv
could
studi
gbvb
anim
model
hcv
proteas
inhibitor
inhibit
gbvb
replic
infect
marmoset
infect
primari
marmoset
hepatocyt
antivir
natur
ribavirin
explor
use
gbvb
model
well
data
suggest
incorpor
ribavirin
triphosph
rna
polymeras
induc
errorpron
replic
concomit
reduct
infect
induct
errorpron
replic
ribavirin
demonstr
hcv
replicon
model
marmoset
tamarin
interferon
alpha
ifna
interferon
gamma
ifng
potent
antivir
activ
gbvb
vitro
similar
observ
hcv
vitro
new
studi
focus
interferon
lambda
ifnl
focu
ifnl
pathway
base
find
snp
locu
human
popul
exert
enorm
effect
viral
clearanc
acut
infect
ifna
therapi
yet
mechan
involv
understood
ifnl
human
includ
genom
area
marmoset
encod
interferon
lambda
sequenc
marmoset
lack
human
transcript
orient
suggest
human
homologu
present
human
homologu
absent
thu
gene
duplic
give
rise
may
occur
segreg
new
old
world
primat
vitro
vivo
studi
conduct
character
antivir
activ
gbvb
infect
marmoset
except
potent
antivir
activ
demonstr
class
ifn
marmoset
lanford
unpublish
data
clearli
potent
antivir
agent
ifna
model
one
anim
undetect
viremia
dose
week
therapi
repres
declin
log
viremia
greater
declin
observ
potent
directact
antivir
hcv
marmoset
increasingli
becom
chosen
primat
model
transgen
newer
technolog
emerg
effici
gene
disrupt
eg
crispr
method
need
transient
examin
phenotyp
gene
knockdown
model
invest
transgen
approach
marmoset
model
gbvb
infect
use
examin
potenti
gene
knockdown
use
system
inject
antisens
use
novel
lock
nucleic
acid
lna
antisens
technolog
lna
technolog
first
use
antivir
studi
demonstr
sequestr
could
knockdown
hcv
replic
chimpanze
highli
abund
liverspecif
microrna
hcv
two
bind
site
ncr
essenti
maintain
hcv
replic
lna
antisens
progress
phase
ii
clinic
trial
hcv
miravirsen
show
highli
potent
antivir
activ
proof
concept
lna
technolog
work
expect
marmoset
model
miravirsen
use
gbvb
antivir
studi
marmoset
gbvb
two
bind
site
ident
space
two
site
hcv
vitro
studi
confirm
antivir
effect
miravirsen
use
primari
marmoset
hepatocyt
infect
gbvb
vivo
pretreat
miravirsen
render
marmoset
complet
resist
gbvb
infect
data
clearli
indic
valid
antivir
target
gbvb
lna
technolog
use
gene
knockdown
marmoset
lanford
unpublish
data
marmoset
small
nonhuman
model
gene
knockdown
may
valu
number
differ
research
field
recent
emerg
member
flaviviru
famili
zika
viru
zikv
america
role
fetal
abnorm
place
urgenc
develop
anim
model
zikv
mosquitoborn
infect
associ
neurolog
complic
sever
microcephali
full
extent
advers
event
associ
zikv
infect
pregnant
women
known
year
follow
infant
born
zikvinfect
pregnant
women
recent
male
marmoset
experiment
infect
zikv
reproduc
key
featur
human
diseas
asymptomat
infect
short
window
detect
viru
serum
less
week
also
viru
detect
urin
saliva
semen
stool
least
week
follow
acut
infect
postinfect
persist
lymph
node
saliva
serum
sampl
produc
infecti
viru
cell
cultur
marmoset
develop
neutral
antibodi
respons
activ
nk
cell
b
cell
subset
circul
cytokin
associ
type
ii
interferon
signal
increas
transcriptom
profil
show
enrich
immun
respons
activ
viral
infect
upregul
type
ii
interferon
signal
pathway
studi
examin
role
zikv
pregnant
marmoset
underway
author
believ
marmoset
may
prove
valuabl
model
drug
test
vaccin
develop
understand
pathogenesi
zikv
